Ranibizumab monotherapy for sub-foveal haemorrhage secondary to choroidal neovascularisation in age-related macular degeneration

被引:0
作者
M McKibbin
V Papastefanou
B Matthews
H Cook
L Downey
机构
[1] Eye Clinic,Department of Ophthalmology
[2] St James's University Hospital,undefined
[3] Leeds,undefined
[4] UK,undefined
[5] Hull and East Yorkshire Eye Hospital,undefined
[6] Hull Royal Infirmary,undefined
来源
Eye | 2010年 / 24卷
关键词
ranibizumab; sub-foveal haemorrhage; age-related macular degeneration;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:994 / 998
页数:4
相关论文
共 67 条
[1]  
Avery R(1996)Natural history of subretinal subfoveal haemorrhage in age-related macular degeneration Retina 16 183-189
[2]  
Fekrat S(2004)Surgery for hemorrhagic choroidal neovascular lesions of age-related macular degeneration: ophthalmic findings: SST report no. 13 Ophthalmology 111 1993-2006
[3]  
Hawkins B(2004)Subretinal recombinant tissue plasminogen activator injection and pneumatic displacement of thick submacular hemorrhage in age-related macular degeneration Ophthalmology 111 1201-1208
[4]  
Bressler N(2007)Pneumatic displacement of submacular hemorrhage: safety, efficacy, and patient selection Retina 27 329-334
[5]  
Bressler NM(2006)Management of subretinal macular haemorrhage by direct administration of tissue plasminogen activator Br J Ophthalmol 90 429-431
[6]  
Bressler SB(2009)Management of extensive subfoveal haemorrhage secondary to neovascular age-related macular degeneration Eye 23 1404-1410
[7]  
Childs AL(2007)Intravitreal bevacizumab therapy for neovascular age-related macular degeneration with large submacular hemorrhage Am J Ophthalmol 144 886-892
[8]  
Haller JA(2008)Combined treatment of acute subretinal haemorrhages with intravitreal recombined tissue plasminogen activator, expansile gas and bevacizumab: a retrospective pilot study Acta Ophthalmol 86 490-494
[9]  
Hawkins BS(2006)Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 1419-1431
[10]  
Lewis H(2007)An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration Am J Ophthalmol 143 566-583